F-1/A: Anbio Biotechnology Seeks Waiver for IPO Financial Reporting Requirement

Anbio Biotechnology requests a waiver from the SEC regarding the 12-month financial statement requirement for its initial public offering, citing impracticability and undue hardship.

Summary

• Anbio Biotechnology, a foreign private issuer, is seeking a waiver from the U.S. Securities and Exchange Commission (SEC) regarding the requirement to include audited financial statements not older than 12 months from the date of its initial public offering (IPO).
• The company has filed an amendment to its Registration Statement on Form F-1, initially filed on December 31, 2024, which includes audited financial statements for the years ended December 31, 2023 and 2022, and unaudited interim financial statements as of June 30, 2024.
• Anbio is requesting the waiver because it is not required to comply with the 12-month rule in any other jurisdiction and complying with it is considered impracticable and would cause undue hardship.
• The company anticipates that its audited financial statements for the fiscal year ended December 31, 2024, will not be available until April 2025.
• Anbio has committed that it will not seek effectiveness of the Registration Statement if its audited financial statements are older than 15 months at the time of the IPO.

Sentiment

Score: 6

Explanation: The document is a formal request for a waiver, which is a neutral event. The company is transparent about its situation, but the need for a waiver and the delay in financial reporting could be seen as slightly negative.

Positives

• The company is transparently addressing the financial reporting requirements for its IPO.
• Anbio is proactively seeking a waiver to avoid potential delays.
• The company has committed to not proceeding with the IPO if the financials are older than 15 months, showing a commitment to providing up-to-date information.

Negatives

• The company's audited financial statements for 2024 will not be available until April 2025, which could delay the IPO.
• The need for a waiver indicates a potential challenge in meeting standard reporting timelines.

Risks

• The SEC may not grant the waiver, potentially delaying the IPO.
• The delay in the availability of the 2024 audited financials could impact investor confidence.
• The company's reliance on a waiver could be perceived negatively by some investors.

Future Outlook

The company intends to proceed with its IPO as soon as practicable after the effectiveness of the registration statement, but not if the audited financial statements are older than 15 months.

Management Comments

• Michael Lau, Chief Executive Officer, signed the waiver request on behalf of Anbio Biotechnology.

Industry Context

The request for a waiver highlights the challenges that foreign private issuers may face when aligning their financial reporting timelines with U.S. requirements for an IPO. This is not uncommon, and the SEC has provisions to address such situations.

Comparison to Industry Standards

• The 12-month rule is a standard requirement for IPOs in the US, designed to ensure investors have access to the most recent financial information.
• Companies like BioNTech, which also had a foreign IPO, had to comply with similar requirements, but did not require a waiver.
• Other companies such as Alibaba, which had a foreign IPO, also had to comply with similar requirements, but did not require a waiver.
• The waiver request by Anbio is not unique, but it is not the norm, and indicates a potential challenge in meeting standard reporting timelines.

Stakeholder Impact

• Shareholders may experience a delay in the IPO process.
• Potential investors may need to wait longer for the company to go public.
• The company's reputation could be slightly impacted by the need for a waiver.

Next Steps

• The company will await the SEC's decision on the waiver request.
• The company will file its audited financial statements for the year ended December 31, 2024, when available.
• The company will proceed with the IPO as soon as practicable after the effectiveness of the registration statement, but not if the audited financial statements are older than 15 months.

Key Dates

Keywords

IPO, Waiver, Financial Statements, SEC, Audited Financials, Registration Statement, Form F-1, Anbio Biotechnology